arrow
S

Sandra Heskamp

department of medical imaging
H指数:35
被引数:3,954

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predicting tumour and organ dose in α-radiopharmaceutical therapy: a 89Zr-based dosimetric approach for 225Ac

预测α放射性药物疗法中的肿瘤和器官剂量:基于89Zr的225Ac剂量学方法

2026-07-150
OAAI
Efficacy of combined targeted radionuclide therapy and immune checkpoint Inhibition in animal tumour models: a systematic review and meta-analysis of the literature

联合靶向放射性核素疗法与免疫检查点抑制在动物肿瘤模型中的疗效:文献的系统评价与荟萃分析

2025-04-260
OA
Site-directed multivalent conjugation of antibodies to ubiquitinated payloads

抗体靶向多价缀合至泛素化负载

2025-04-090
OA
European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer

欧洲核医学协会焦点5: 前列腺癌分子成像和治疗诊断共识

2024-01-018
OA
Direct In Vivo Activation of T Cells with Nanosized Immunofilaments Inhibits Tumor Growth and Metastasis

用纳米免疫丝直接体内激活T细胞抑制肿瘤生长和转移

2023-06-207
OAAI
Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand
2023-04-155
OAAI
Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies

成纤维细胞活化蛋白靶向放射性核素治疗: 首次 (前) 临床研究的背景,机遇和挑战

2023-02-2355
OAAI
[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
2022-11-1717
OAAI
89Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer
2022-05-0522
OA